Header image

Breakfast Symposia 3: Cardiovascular risk beyond LDL-C: what can we do about residual risk?

Sunday, November 22, 2026
7:30 - 8:30
Room E1

Details

Presented by CSL Seqirus Despite significant advances in lipid management and the widespread use of statins, many patients remain at risk of cardiovascular events. This educational session will explore the contemporary management of cardiovascular risk beyond LDL-C reduction, with a focus on identifying and addressing residual risk factors in both primary and secondary prevention settings. The presentation will cover an overview of residual cardiovascular risk, and examine the role of triglycerides and other emerging risk markers in overall cardiovascular risk assessment. The session will discuss how residual risk can contribute to ongoing cardiovascular events (despite optimal LDL-C control) and consider evidence-based approaches that clinicians can implement today to further reduce the risk of future cardiovascular events. Through a series of practical cases, the presenter will explore treatment decision-making in real-world scenarios. Case discussions will examine patients who have achieved LDL-C goals but continue to have residual cardiovascular risk, prompting consideration of additional therapeutic and lifestyle interventions. The session will also address the role of newer treatment options in appropriate patient populations, including strategies for primary event prevention and approaches to managing residual risk factors in secondary prevention. At the completion of this session, the audience will be able to; - Describe the concept of residual cardiovascular risk and its impact on patient outcomes.
- Apply current recommendations for LDL-C management in primary and secondary prevention.
- Recognise the contribution of triglycerides and other risk factors driving residual cardiovascular risk.
- Identify evidence-based therapeutic options that may further reduce cardiovascular event risk in appropriate patients.
- Apply learnings to real-world patient cases and develop practical management strategies that can be implemented immediately in clinical practice.


Speaker

Agenda Item Image
Dr Kathryn Waddell-Smith
Genetic Cardiologist
Royal Adelaide Hospital, Flinders Medical Centre, Women’s and Children’s Hospital, Nightingale Cardiology

Cardiovascular risk beyond LDL-C: what can we do about residual risk?

Dr Kathryn Waddell-Smith is a General Cardiologist with a special interest in Genetic Cardiology and stress echocardiography. Dr Waddell-Smith is South Australia’s first and only Genetic Cardiologist, and is a Staff Specialist across SA Health hospitals.  She trained in Adelaide and the Northern Territory before completing five years of overseas fellowship in Auckland, New Zealand and Cambridge, United Kingdom. Kathryn has significant expertise, including a PhD, in inherited cardiac conditions such as long QT and Brugada syndromes, CPVT and inherited cardiomyopathies such as hypertrophic, dilated and arrhythmogenic cardiomyopathies and sudden unexpected death. Dr Waddell-Smith also has an interest in high cholesterol issues and can arrange genetic testing for this when appropriate. Dr Waddell-Smith is the past Chair of the Cardiac Society of Australia and New Zealand Genetics Council and is a Senior Clinical Lecturer at Flinders University. She is well published in peer-reviewed international journals, is actively involved in scientific committees of international meetings and enjoys teaching at all levels.
loading